Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Llovet, Josep M ^a,b,c   Paradis, Valerie ^d   Kudo, Masatoshi ^e   Zucman Rossi, Jessica ^f,g  

^a HOSPITAL CLÍNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d CNRS   (France)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Labex Immuno Oncology   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR; ERLOTINIB; IMATINIB; MICRORNA; PANITUMUMAB; SCATTER FACTOR; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; SORAFENIB; TRASTUZUMAB; TUMOR MARKER; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; DONOR SELECTION; GASTROINTESTINAL STROMAL TUMOR; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053224170     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22340     Document Type: Article

References (41)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
2. Llovet JM, Schwartz M, Mazzaferro V,. Resection and transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
3. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
4. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST,. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-1360. (Pubitemid 39331462)
5. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S,. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-312. (Pubitemid 40129290)
6. Kaposi-Novak P, Lee JS, Gamez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS,. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006; 116: 1582-1595.
7. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM,. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-328.
8. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
9. Bruix J, Sherman M,; for American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
10. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005; 42: 809-818. (Pubitemid 41401118)
11. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-947. (Pubitemid 46646500)
12. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767. (Pubitemid 46001394)
13. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45: 725-734. (Pubitemid 46450624)
14. Llovet JM, Bruix J,. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (suppl 1): S20-S37.
15. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF,. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-1596.
16. Sawyers CL,. The cancer biomarker problem. Nature 2008; 452: 548-552. (Pubitemid 351483368)
17. Okuda K, Tanaka M, Kanazawa N, Nagashima J, Satomura S, Kinoshita H, et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by Lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol 1999; 14: 265-271.
18. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27: 5734-5742.
19. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y,. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010; 55: 3576-3583.
20. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010; 16: 4688-4694.
21. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-1461. (Pubitemid 351346853)
22. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024.
23. Boyault S, Rickman DS, de Reynias A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52. (Pubitemid 46144363)
24. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
25. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111. (Pubitemid 44202603)
26. Llovet JM, Peña C, Shan M, Lathia C, Bruix J,. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Paper presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31-November 4, 2008; San Francisco, CA.
27. Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008; 49: 581-588.
28. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166. (Pubitemid 351163165)
29. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773. (Pubitemid 32523494)
30. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Cui X, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 2008; 39: 1777-1783.
31. Weinstein IB, Joe A,. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.; for Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
33. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792. (Pubitemid 40271173)
34. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-3147.
35. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-2629.
36. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
37. Ferté C, André F, Soria JC,. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-380.
38. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM,. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.
39. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
40. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
41. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)